The global platelet
aggregation devices market size
is expected to reach USD 1,556.8 million by 2027 according to a new study by
Polaris Market Research. Platelet aggregation is the biological
process where the platelet cells are employed in a process to prevent bleeding
through vaso-constriction for rapid clot formation. The whole process is
mediated via platelet aggregating factor (PAF). The quantitative and
qualitative defects of platelets lead to increased bleeding. The high
reactivity of platelets in the patients having anti-platelet therapy results in
thromboembolic complications.
Platelet
function related disorders can be either inherited or acquired. The inherited
platelet function disorders include Von Willebrand disease, Glanzmann’s
thrombasthenia, Bernard-Soulier syndrome, Storage pool disease. The acquired
platelet dysfunction may be caused by chronic conditions such as kidney failure
(uremia), Myelodysplastic syndrome (MDS), Leukemias (chronic myeloid leukemia
or CML; acute myeloid leukemia or AML).
Request A Sample Report at : https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-sample
![]() |
| Know more about this report: Get PDF Brochure |
Some acquired platelet disorders are temporary because of the
decreased function of platelets due to anti-platelet medications, non-steroidal
anti-inflammatory drugs (NSAIDs), tricyclic antidepressants, antihistamines and
some antibiotics. The platelet function testing is transitioned from
diagnostics for heritable diseases to a functional one for platelet functional
therapies. The rapid usage of anti-platelet therapy, mainly dual anti-platelet
therapy has changed the focus of platelet function testing from diagnostics to
therapeutics.
The
market is driven by few notable factors such as the recent surge in infectious
diseases (COVID-19) requiring rapid serological tests, innovations in platelet
aggregation mechanisms, systems and consumables, and worldwide rise in chronic
ailments. Specialized tests based on platelet aggregation include light
transmission platelet aggregometry on platelet-rich plasma (LTA), impedance
whole blood aggregometry (WBA), Lumi-aggregometry and flow cytometry.
Automated
haematology analyzers can be used to obtain platelet counts over a wide range
of values using optical counting methods like light scatter or fluorescence.
Screening tests such as prothrombin time (PT) or activated partial
thromboplastin time (aPTT) are more standardized and fully automated.
Request for Discount Pricing with Your
Specific Research Needs At : https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-discount-pricing
Number of
reagents are available in the market to carry out the platelet function tests.
These reagents include collagen, thrombin, ADP, vasopressin, epinephrine and
ristocetin. Collagen, ADP were used in routine platelet aggregation studies for
the evaluation of qualitative platelet function disorders.
Market
participants such as F. Hoffmann La-Roche Ltd., Drucker
Diagnostics, Haemonetics Corporation, Sysmex Corporation, Siemens Healthineers,
Chrono-log Corporation, Instrumentation Laboratory, Accriva Diagnostics, Matis
Medical, Helena Laboratories Corporation, Sienco, Inc., Bio/Data Corporation,
Tem Group, WerfenLife, S.A., Laboratory Corporation of America Holdings,
Sentinel CH. S.p.A., and Aggredyne, Inc. are some of the key players operating
in the concerned market.
Have Questions? Or make an Inquiry before buying this report Speak
to Our Industry Expert: https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/speak-to-analyst

No comments:
Post a Comment
Please do not enter any spam link in the comment box...